Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196), has announced that its licensed injection filler product, Prohiro, has had its market filing accepted for review by China’s National Medical Products Administration (NMPA). Profhilo, an injectable sodium hyaluronate solution, is recognized as one of the highest concentration hyaluronic acid products available. The product utilizes NAHYCO’s patented mixing technology to stabilize molecules and is free from crosslinking agents such as BDDE, which can stimulate the regeneration of natural collagen and elastin.
Profhilo differentiates itself from other subcutaneous fillers by acting on multiple levels within the skin, including the stratum corneum, dermis, and subcutaneous tissue. This approach allows it to reshape the skin, treat skin sagging, and achieve anti-aging effects. Additionally, the product can support other subcutaneous filling treatments and cosmetic surgeries.
Developed by IBSA and holding CE marks, Profhilo has garnered global recognition for its safety and efficacy. In 2018, Sisram entered into a partnership with ISBA, securing exclusive agency rights for the product in Israel, India, mainland China, and Hong Kong. The product is already commercially available in the other three regions.- Flcube.com
